esketamine + dexmedetomidine

Esketamine + dexmedetomidine is a combination of two small molecule drugs used primarily for their synergistic sedative, analgesic, and neuroprotective effects. Esketamine is the S-enantiomer of ketamine, acting as a noncompetitive antagonist at N-methyl-D-aspartate (NMDA) receptors, with additional activity at GABA receptors. It provides potent analgesia and sedation and has rapid-acting antidepressant properties. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that produces sedation, anxiolysis, mild analgesia, and sympatholytic effects without significant respiratory depression. The combination leverages complementary mechanisms: esketamine can counteract bradycardia and hypotension caused by dexmedetomidine while enhancing overall sedative/analgesic efficacy; dexmedetomidine may reduce tachycardia/hypertension or psychomimetic side effects from esketamine[1][2][4][5][6]. This drug pairing has been studied in perioperative pain management (e.g., after scoliosis surgery), pediatric preoperative sedation (intranasal route), reduction of visceral pain during cesarean section under anesthesia, prevention of postoperative cognitive dysfunction in elderly patients, ICU sedation to reduce delirium risk in mechanically ventilated patients, and as an adjunct for treatment-resistant depression with insomnia[1][2][3][4][5][6][7][9].

Other names

esketamine and dexmedetomidine combinationdexmedetomidine-esketamine combination